Sign In
Buy IKT
$1.70
-0.0100 (-0.585%)
At Close: Jun 02, 2026
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
08:05am, Tuesday, 19'th Oct 2021
ATLANTA, Oct. 19, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di
IKT Stock: Why It Increased Today
08:36am, Monday, 04'th Oct 2021
The stock price of Inhibikase Therapeutics, Inc. (Nasdaq: IKT) increased over 5% pre-market today. This is why it happened.
ATLANTA, Oct. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
ATLANTA, Sept. 23, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity
04:45pm, Monday, 16'th Aug 2021
ATLANTA, Aug. 16, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di
Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients
08:42am, Monday, 26'th Jul 2021
ATLANTA, July 26, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of
Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock
06:45pm, Friday, 18'th Jun 2021
ATLANTA, June 18, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di
IKT Stock Price Falls Over 25% Pre-Market: Why It Happened
05:00am, Wednesday, 16'th Jun 2021
The stock price of Inhibikase Therapeutics Inc (NASDAQ: IKT) fell by over 25% pre-market. This is why it happened.
Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock
07:40pm, Tuesday, 15'th Jun 2021
ATLANTA, June 15, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di
Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
04:05pm, Monday, 17'th May 2021
ATLANTA, May 17, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's dis
Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum
08:00am, Wednesday, 21'st Apr 2021
ATLANTA, April 21, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's di
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
08:00am, Thursday, 01'st Apr 2021
ATLANTA, April 1, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease (PD) an
Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference
08:05am, Monday, 22'nd Feb 2021
ATLANTA, Feb. 22, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related dis
ATLANTA--(BUSINESS WIRE)--Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and rela
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
03:43pm, Saturday, 16'th Jan 2021
U.S. IPO Week Ahead: Foreign Issuers Dominate A 4-IPO Week
